PDRADIOPHARMA INC.

Curium, PeptiDream and PDRadiopharma Complete Patient Dosing in Phase 2 Trial of 64Cu-PSMA-I&T PET Diagnostic for Prostate Cancer in Japan

- Patient dosing has been completed in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA on prostate cancer cells, in Japan. - The open-label, single-arm study is evaluating sensitivity, specificity, and safety in Japanese patients newly diagnosed with unfavorable intermediate, high, or very high-risk prostate cancer. - Data analysis is now underway, with results expected to support a future regulatory submission in Japan alongside Curium's ongoing global clinical trials. - A parallel registrational trial of the therapeutic counterpart 177Lu-PSMA-I&T is advancing in metastatic castration-resistant prostate cancer as part of a theranostic approach.